Boston, MA 09/03/2014 (wallstreetpr) – As per the reports, Boston Scientific Corporation (NYSE:BSX) has released the results of WallFlex Biliary RX Stent study which was conducted by the company some time back. The study led to positive results that have been published in the latest issue of prominent journal Gastroenterology.
Primary purpose of study:
The main objective of this study was to understand the safety and efficiency of FCSEMS (fully covered self-expanding metal stents) in benign bile duct strictures patients for the treatment of biliary obstruction. There was not any clarity about the frequency with which the biliary obstruction should be executed in a long run; hence this study tried to find a suitable solution of this question as well.
How was it conducted:
Boston Scientific Corporation (NYSE:BSX) selected 187 benign bile duct stricture patients and implanted them with the fully covered WallFlex Biliary RX Stent. It was conducted at 13 centers of the company in 11 countries across five continents. As per the reports, WallFlex Biliary RX Stent of BSX has been awarded CE Mark in Europe for benign biliary strictures therapy and for curing biliary strictures. Healthcare experts decided to remove these stents to deduce treatment success after the extension of up to 12 months to indwell.
Results:
According to reports published by Boston Scientific Corporation (NYSE:BSX), the results of the study were 100% positive. All the 155 people who took the treatment experienced the complete endoscopic removal of FCSEMS. Even after the extended indwell and stricture resolution, the success rate of FCSEMS removal was recorded around 75% that was more than the average. The stricture resolution rates among those patients who underwent FCSEMS removal were recorded as 90.1%. Due to this study, the treatment of FCSEMS did not only become easy, but cost-effective as well.
A follow-up of all the patients who have undergone the treatment will be done after five years to check the long-term durability of the treatment.
